Skip to Content

'
Jian Gu, Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1998 Baylor College of Medicine, Houston, TX, PHD, Molecular Biology
1993 Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Shanghai, MS, Molecular Pharmacology
1990 Nankai University, Tianjing, BS, Biology

Selected Publications

Peer-Reviewed Original Research Articles

1. Wang Y, Gu J, Roth JA, Hildebrandt MA, Lippman SM, Ye Y, Minna JD, Wu X. Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non-Small Cell Lung Cancer. Cancer Res 73(15):4801-9, 8/2013. e-Pub 6/2013. PMID: 23774211.
2. Xu E, Sun W, Gu J, Chow WH, Ajani JA, Wu X. Association of mitochondrial DNA copy number in peripheral blood leukocytes with risk of esophageal adenocarcinoma. Carcinogenesis. e-Pub 7/2013. PMID: 23803692.
3. Xu E, Gong Y, Gu J, Jie L, Ajani JA, Wu X. Risk assessment of esophageal adenocarcinoma using γ-H2AX assay. Cancer Epidemiol Biomarkers Prev. e-Pub 7/2013. PMID: 23904462.
4. Xie H, Wu X, Wang S, Chang D, Pollock RE, Lev D, Gu J. Long telomeres in peripheral blood leukocytes are associated with an increased risk of soft tissue sarcoma. Cancer 119(10):1885-91, 5/2013. e-Pub 2/2013. PMID: 23408253.
5. Xie H, Lev D, Gong Y, Wang S, Pollock RE, Wu X, Gu J. Reduced mitochondrial DNA copy number in peripheral blood leukocytes increases the risk of soft tissue sarcoma. Carcinogenesis 34(5):1039-43, 5/2013. e-Pub 1/2013. PMID: 23349016.
6. Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila) 6(3):196-205, 3/2013. PMCID: PMC3608471.
7. He Y, Gong Y, Lin J, Chang DW, Gu J, Roth JA, Wu X. Ionizing radiation-induced γ-H2AX activity in whole blood culture and the risk of lung cancer. Cancer Epidemiol Biomarkers Prev. e-Pub 1/2013. PMID: 23300022.
8. Lin M, Eng C, Hawk ET, Huang M, Lin J, Gu J, Ellis LM, Wu X. Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. Cancer 118(24):6188-98, 12/2012. e-Pub 6/2012. PMCID: PMC3465518.
9. Pu X, Ye Y, Spitz MR, Wang L, Gu J, Lippman SM, Hildebrandt MA, Hong WK, Minna JD, Roth JA, Yang P, Wu X. Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study. Clin Cancer Res 18(21):5983-91, 11/2012. e-Pub 9/2012. PMCID: PMC3640870.
10. Lin J, Lu C, Stewart DJ, Gu J, Huang M, Chang DW, Lippman SM, Wu X. Systematic Evaluation of Apoptotic Pathway Gene Polymorphisms and Lung Cancer Risk. Carcinogenesis 33(9):1699-706., 9/2012. PMID: 22665367.
11. Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, Huang M, Calin GA, Wang D, Dubois RN, Hawk ET, Wu X. Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients. Clin Cancer Res 18(14):3982-91, 7/2012. PMID: 22661538.
12. Dai J, Gu J, Huang M, Eng C, Kopetz ES, Ellis LM, Hawk E, Wu X. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis 33(7):1327-31, 7/2012. PMID: 22505654.
13. Lin M, Eng C, Hawk ET, Huang M, Greisinger AJ, Gu J, Ellis LM, Wu X, Lin J. Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. Carcinogenesis 33(4):841-7, 4/2012. e-Pub 2/8/2012. PMCID: PMC3324446.
14. Wu X, Scelo G, Purdue MP, Rothman N, Johansson M, Ye Y, Wang Z, Zelenika D, Moore LE, Wood CG, Prokhortchouk E, Gaborieau V, Jacobs KB, Chow WH, Toro JR, Zaridze D, Lin J, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Jinga V, Bencko V, Slamova A, Holcatova I, Navratilova M, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL, Boeing H, Vineis P, Clavel-Chapelon F, Palli D, Tumino R, Krogh V, Panico S, Duell EJ, Quirós JR, Sanchez MJ, Navarro C, Ardanaz E, Dorronsoro M, Khaw KT, Allen NE, Bueno-de-Mesquita HB, Peeters PH, Trichopoulos D, Linseisen J, Ljungberg B, Overvad K, Tjønneland A, Romieu I, Riboli E, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Virtamo J, Vatten L, Hveem K, Fletcher T, Koppova K, Cussenot O, Cancel-Tassin G, Benhamou S, Hildebrandt MA, Pu X, Foglio M, Lechner D, Hutchinson A, Yeager M, Fraumeni JF, Lathrop M, Skryabin KG, McKay JD, Gu J, Brennan P, Chanock SJ. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet 21(2):456-62., 1/15/2012. e-Pub 10/18/2011. PMCID: PMC3276284.
15. Xing J, Dinney CP, Shete S, Huang M, Hildebrandt MA, Chen Z, Gu J. Comprehensive pathway-based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of bladder cancer. Cancer 118(1):205-15, 1/2012. e-Pub 6/2011. PMCID: PMC3178723.
16. Chang J, Dinney CP, Huang M, Wu X, Gu J. Genetic variants in telomere-maintenance genes and bladder cancer risk. PLoS One 7(2):e30665, 2012. e-Pub 2/2012. PMCID: PMC3281862.
17. Andrew AS, Hu T, Gu J, Gui J, Ye Y, Marsit CJ, Kelsey KT, Schned AR, Tanyos SA, Pendleton EM, Mason RA, Morlock EV, Zens MS, Li Z, Moore JH, Wu X, Karagas MR. HSD3B and Gene-Gene Interactions in a Pathway-Based Analysis of Genetic Susceptibility to Bladder Cancer. PLoS One 7(12):e51301, 2012. e-Pub 12/2012. PMCID: PMC3526593.
18. Pan JY, Ajani JA, Gu J, Gong Y, Quin A, Hung M, Wu X, Izzo JG. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer. e-Pub 12/27/2011. PMID: 22213102.
19. Yin J, Lu C, Gu J, Lippman SM, Hildebrandt MA, Lin J, Stewart D, Spitz MR, Wu X. Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer. Carcinogenesis 32(12):1867-71, 12/2011. e-Pub 9/28/2011. PMCID: PMC3220611.
20. Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Malats N, Dinney CP, Chatterjee N, Prokunina-Olsson L, Wang Z, Lin J, Real FX, Jacobs KB, Baris D, Thun M, De Vivo I, Albanes D, Purdue MP, Kogevinas M, Kamat AM, Lerner SP, Grossman HB, Gu J, Pu X, Hutchinson A, Fu YP, Burdett L, Yeager M, Tang W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G, Grubb R, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Hunter DJ, Caporaso N, Landi MT, Fraumeni JF, Silverman DT, Chanock SJ, Wu X. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet 20(21). e-Pub 8/2011. PMID: 21824976.
21. Lin M, Stewart DJ, Spitz MR, Hildebrandt MA, Lu C, Lin J, Gu J, Huang M, Lippman SM, Wu X. Genetic variations in the transforming growth factor beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis 32(7):1050-6, 7/2011. e-Pub 4/22/2011. PMCID: PMC3128559.
22. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang P. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst 103(10):817-25, 5/2011. e-Pub 4/2011. PMCID: PMC3096796.
23. Gu J, Chen M, Shete S, Amos CI, Kamat A, Ye Y, Lin J, Dinney CP, Wu X. A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res (Phila) 4(4):514-21, 4/2011. e-Pub 4/2/2011. PMCID: PMC3076128.
24. Gu J, Ye Y, Spitz MR, Lin J, Kiemeney LA, Xing J, Hildebrandt MA, Ki Hong W, Amos CI, Wu X. A genetic variant near the PMAIP1/Noxa gene is associated with increased bleomycin sensitivity. Hum Mol Genet 20(4):820-6, 2/2011. e-Pub 11/2010. PMCID: PMC3024041.
25. Lee JJ, Wu X, Hildebrandt MA, Yang H, Khuri FR, Kim E, Gu J, Ye Y, Lotan R, Spitz MR, Hong WK. Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) 4(2):185-93, 2/2011. PMID: 21292633.
26. Pu X, Hildebrandt MA, Lu C, Lin J, Stewart DJ, Ye Y, Gu J, Spitz MR, Wu X. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer 71(1):82-8, 1/2011. e-Pub 5/2010. PMCID: PMC2952281.
27. Dai J, Gu J, Lu C, Lin J, Stewart D, Chang D, Roth JA, Wu X. Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer. PLoS One 6(6):e21120, 2011. e-Pub 6/2011. PMCID: PMC3117866.
28. Sigurdson AJ, Jones IM, Wei Q, Wu X, Spitz MR, Stram D, Gross MD, Huang WY, Wang LE, Gu J, Thomas CB, Reding D, Hayes RB, Caporaso NE. Prospective Analysis of DNA Damage and Repair Markers of Lung Cancer Risk From the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Carcinogenesis 32(1):69-73, 2011. e-Pub 10/2010. PMID: 20929901.
29. Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, Gu J, Wu X, Lu K. Genetic Variants in MicroRNA Biosynthesis Pathways and Binding Sites Modify Ovarian Cancer Risk, Survival, and Treatment Response. Cancer Res 70(23):9765-76, 12/2010. e-Pub 11/2010. PMID: 21118967.
30. Chen M, Hildebrandt MA, Clague J, Kamat AM, Picornell A, Chang J, Zhang X, Izzo J, Yang H, Lin J, Gu J, Chanock S, Kogevinas M, Rothman N, Silverman DT, Garcia-Closas M, Grossman HB, Dinney CP, Malats N, Wu X. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila) 3(10):1235-45, 10/2010. e-Pub 9/2010. PMCID: PMC2955764.
31. Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P, Wood CG, Wu X. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 29(42):5724-8, 10/2010. e-Pub 8/2010. PMID: 20676129.
32. Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Wang KK, Wu X. Chromosomal Aberrations Predict Malignant Progression of Esophageal Adenocarcinoma: a Genome-wide High-Density SNP Array Analysis. Cancer Prev Res (Phila) 3(9):1176-86, 9/2010. e-Pub 7/2010. PMID: 20651033.
33. Chen M, Gu J, Delclos GL, Killary AM, Fan Z, Hildebrandt MA, Chamberlain RM, Grossman HB, Dinney CP, Wu X. Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis 31(8):1387-91, 8/2010. e-Pub 6/2010. PMCID: PMC2915631.
34. Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, Lu C, Stewart DJ, Minna JD, Roth JA, Lippman SM, Cox JD, Hong WK, Spitz MR, Wu X. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One 5(8):e12402, 2010. e-Pub 8/2010. PMCID: PMC2928273.
35. Xing J, Ajani JA, Chen M, Izzo J, Lin J, Chen Z, Gu J, Wu X. Constitutive Short Telomere Length of Chromosome 17p and 12q but not 11q and 2p Is Associated with an Increased Risk for Esophageal Cancer. Cancer Prev Res (Phila Pa) 2(5):459-65, 2009. e-Pub 4/2009. PMCID: PMC2701666.
36. Lin J, Kamat A, Gu J, Chen M, Dinney CP, Forman MR, Wu X. Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk. Cancer Epidemiol Biomarkers Prev 18(7):2090-7, 2009. e-Pub 6/2009. PMID: 19549811.
37. Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G, Seminara D, Yoshida T, Saeki N, Andrew AS, Dinney CP, Czerniak B, Zhang ZF, Kiltie AE, Bishop DT, Vineis P, Porru S, Buntinx F, Kellen E, Zeegers MP, Kumar R, Rudnai P, Gurzau E, Koppova K, Mayordomo JI, Sanchez M, Saez B, Lindblom A, de Verdier P, Steineck G, Mills GB, Schned A, Guarrera S, Polidoro S, Chang SC, Lin J, Chang DW, Hale KS, Majewski T, Grossman HB, Thorlacius S, Thorsteinsdottir U, Aben KK, Witjes JA, Stefansson K, Amos CI, Karagas MR, Gu J. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 41(9):991-995, 2009. e-Pub 8/2009. PMID: 19648920.
38. Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, Yang H, Hildebrandt MA, Lin J, Ye Y, Chamberlain RM, Dinney CP, Wu X. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis 30(12):2047-52, 2009. PMCID: PMC2792319.
39. Chen M, Ye Y, Yang H, Tamboli P, Matin S, Tannir NM, Wood CG, Gu J, Wu X. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer 125(10):2342-8, 2009. e-Pub 6/2009. PMCID: PMC2768265.
40. Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, Ajani JA, Wu X. MicroRNA Expression Signatures in Barrett's Esophagus and Esophageal Adenocarcinoma. Clin Cancer Res 15(18):5744-52, 2009. e-Pub 9/2009. PMCID: PMC2745487.
41. Wu X, Spitz MR, Lee JJ, Lippman SM, Ye Y, Yang H, Khuri FR, Kim E, Gu J, Lotan R, Hong WK. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila Pa) 2(7):617-24, 2009. PMID: 19584075.
42. Reyes-Gibby CC, Spitz MR, Yennurajalingam S, Swartz M, Gu J, Wu X, Bruera E, Shete S. Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiol Biomarkers Prev 18(10):2636-42, 2009. e-Pub 9/2009. PMCID: PMC2759856.
43. Gu J, Horikawa Y, Chen M, Dinney CP, Wu X. Benzo(a)pyrene diol epoxide-induced chromosome 9p21 aberrations are associated with increased risk of bladder cancer. Cancer Epidemiol Biomarkers Prev 17(9):2445-50, 2008. PMID: 18768515.
44. Ye Y, Yang H, Grossman HB, Dinney C, Wu X, Gu J. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer 112(11):2467-74, 2008. PMID: 18361427.
45. Ye Y, Wang KK, Gu J, Yang H, Lin J, Ajani JA, Wu X. Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila Pa) 1(6):460-9, 2008. PMID: 19138993.
46. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, Sullivan K, Matakidou A, Wang Y, Mills G, Doheny K, Tsai YY, Chen WV, Shete S, Spitz MR, Houlston RS. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 40(5):616-22, 2008. PMID: 18385676.
47. Wu X, Lu C, Ye Y, Chang J, Yang H, Lin J, Gu J, Hong WK, Stewart D, Spitz MR. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 18(11):955-65, 2008. PMID: 18854777.
48. Xing J, Chen M, Wood CG, Lin J, Spitz MR, Ma J, Amos CI, Shields PG, Benowitz NL, Gu J, de Andrade M, Swan GE, Wu X. Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst 100(15):1104-12, 2008. PMID: 18664653.
49. Zhu Y, Yang H, Chen Q, Lin J, Grossman HB, Dinney CP, Wu X, Gu J. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. DNA Repair (Amst) 7(2):141-8, 2008. PMID: 17923445.
50. Yang H, Gu J, Lin X, Grossman HB, Ye Y, Dinney CP, Wu X. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res 14(7):2236-44, 2008. PMID: 18381966.
51. Xing J, Wu X, Vaporciyan AA, Spitz MR, Gu J. Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer. Cancer 112(12):2756-64, 2008. PMID: 18457328.
52. Horikawa Y, Wood CG, Yang H, Zhao H, Ye Y, Gu J, Lin J, Habuchi T, Wu X. Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res 14(23):7956-62, 2008. PMID: 19047128.
53. Chen M, Kamat AM, Huang M, Grossman HB, Dinney CP, Lerner SP, Wu X, Gu J. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis 28(10):2160-5, 2007. e-Pub 8/2007. PMID: 17728339.
54. Chen M, Gu J, Xing J, Spitz MR, Wu X. Irradiation-induced telomerase activity and the risk of lung cancer: a pilot case-control study. Cancer 109(6):1157-63, 2007. PMID: 17265522.
55. Kader AK, Liu J, Shao L, Dinney CP, Lin J, Wang Y, Gu J, Grossman HB, Wu X. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res 13(9):2614-20, 2007. PMID: 17473191.
56. Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, Follen M, Wu X. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 107(1 Suppl 1):S223-9, 2007. e-Pub 9/2007. PMID: 17825393.
57. Lin J, Swan GE, Shields PG, Benowitz NL, Gu J, Amos CI, de Andrade M, Spitz MR, Wu X. Mutagen sensitivity and genetic variants in nucleotide excision repair pathway: genotype-phenotype correlation. Cancer Epidemiol Biomarkers Prev 16(10):2065-71, 2007. e-Pub 10/2007. PMID: 17932354.
58. Gu J, Gong Y, Huang M, Lu C, Spitz MR, Wu X. Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis 28(2):350-5, 2007. PMID: 16926177.
59. Wu X, Lin J, Grossman HB, Huang M, Gu J, Etzel CJ, Amos CI, Dinney CP, Spitz MR. Projecting Individualized Probabilities of Developing Bladder Cancer in Caucasians. J Clin Oncol 25(31):4974-81, 2007. e-Pub 11/2007. PMID: 17971596.
60. Milam MR, Gu J, Yang H, Celestino J, Wu W, Horwitz IB, Lacour RA, Westin SN, Gershenson DM, Wu X, Lu KH. STK15 F31I Polymorphism is associated with Increased Uterine Cancer Risk: A Pilot Study. Gynecol Oncol 107(1):71-4, 2007. e-Pub 6/2007. PMID: 17599395.
61. Engels EA, Wu X, Gu J, Dong Q, Liu J, Spitz M. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res 67:6520-7, 2007. e-Pub 6/2007. PMID: 17596594.
62. Gu J, Wu X, Dong Q, Romeo MJ, Lin X, Gutkind JS, Berman DM. A nonsynonymous single-nucleotide polymorphism in the PDZ-Rho guanine nucleotide exchange factor (Ser1416Gly) modulates the risk of lung cancer in Mexican Americans. Cancer 106(12):2716-24, 2006. PMID: 16691626.
63. Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, Spitz MR, Wu X. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 12(24):7329-38, 2006. PMID: 17189404.
64. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE, Lerner S, Dinney CP, Spitz MR. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 78(3):464-79, 2006. PMID: 16465622.
65. Schabath MB, Wu X, Wei Q, Li G, Gu J, Spitz MR. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 15(1):158-61, 2006. PMID: 16434604.
66. Huang M, Spitz MR, Gu J, Lee JJ, Lin J, Lippman SM, Wu X. Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. Carcinogenesis 27(10):2034-7, 2006. e-Pub 4/2006. PMID: 16638786.
67. Lin X, Gu J, Lu C, Spitz MR, Wu X. Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer. Clin Cancer Res 12(19):5720-5, 2006. PMID: 17020976.
68. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24(23):3789-98, 2006. PMID: 16785472.
69. Wu X, Gu J, Dong Q, Huang M, Do KA, Hong WK, Spitz MR. Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res 12(23):7194-201, 2006. PMID: 17145846.
70. Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, Gu J, Grossman HB, Wu X. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res 66(24):11644-8, 2006. PMID: 17178858.
71. Wu X, Spitz MR, Amos CI, Lin J, Shao L, Gu J, de Andrade M, Benowitz NL, Shields PG, Swan GE. Mutagen sensitivity has high heritability: evidence from a twin study. Cancer Res 66(12):5993-6, 2006. PMID: 16778168.
72. Gu J, Liang D, Wang Y, Lu C, Wu X. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat Res 581(1-2):97-104, 2005. PMID: 15725609.
73. Gu J, Zhao H, Dinney CP, Zhu Y, Leibovici D, Bermejo CE, Grossman HB, Wu X. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res 11(4):1408-15, 2005. PMID: 15746040.
74. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 23(24):5746-56, 2005. PMID: 16110031.
75. Gu J, Spitz MR, Zhao H, Lin J, Grossman HB, Dinney CP, Wu X. Roles of tumor suppressor and telomere maintenance genes in cancer and aging--an epidemiological study. Carcinogenesis 26:1741-7, 2005. PMID: 15905204.
76. Wu S, Zhu H, Gu J, Zhang L, Teraishi F, Davis JJ, Jacob DA, Fang B. Induction of apoptosis and down-regulation of Bcl-XL in cancer cells by a novel small molecule, 2[[3-(2,3-dichlorophenoxy)propyl]amino]ethanol. Cancer Res 64(3):1110-3, 2004. PMID: 14871845.
77. Gu J, Zhang L, Swisher SG, Liu J, Roth JA, Fang B. Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis. Oncogene 23:1300-7, 2004. PMID: 14676844.
78. Huang X, Lin T, Gu J, Zhang L, Roth JA, Liu J, Fang B. Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene. Int J Oncol 22(6):1241-5, 2003. PMID: 12738989.
79. Lin T, Zhang L, Davis J, Gu J, Nishizaki M, Ji L, Roth JA, Xiong M, Fang B. Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. Mol Ther 8(3):441-8, Jul-Aug, 2003. PMID: 12946317.
80. Lin T, Gu J, Zhang L, Davis JJ, Huang X, Cabbini G, Ji L, Fang B. Enhancing adenovirus-mediated gene transfer in vitro and in vivo by addition of protamine and hydrocortisone. J Gene Med 5(10):868-75, Jul-Aug, 2003. PMID: 14533195.
81. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9(1):93-101, 2003. PMID: 12538456.
82. Gu J, Zhang L, Huang X, Lin T, Yin M, Xu K, Ji L, Roth JA, Fang B. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. Oncogene 21(31):4757-64, 2002. PMID: 12101414.
83. Pirocanac EC, Nassirpour R, Yang M, Wang J, Nardin SR, Gu J, Fang B, Moossa AR, Hoffman RM, Bouvet M. Bax-induction gene therapy of pancreatic cancer. J Surg Res 106(2):346-351, 2002. PMID: 12175991.
84. Huang X, Lin T, Gu J, Zhang L, Roth JA, Stephens LC, Yu Y, Liu J, Fang B. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther 9:1379-86, 2002. PMID: 12365003.
85. Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther 9:30-7, 2002. PMID: 11850720.
86. Tanyi JL, Lapushin R, Eder A, Auersperg N, Tabassam FH, Roth JA, Gu J, Fang B, Mills GB, Wolf J. Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells. Gynecol Oncol 85(3):451-8, 2002. PMID: 12051873.
87. Lin T, Huang X, Gu J, Zhang L, Roth JA, Xiong M, Curley SA, Yu Y, Hunt KK, Fang B. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 21(52):8020-8, 2002. PMID: 12439752.
88. Zhang L, Gu J, Lin T, Huang X, Roth JA, Fang B. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. Gene Ther 9:1262-70, 2002. PMID: 12215894.
89. Lin T, Gu J, Zhang L, Huang X, Stephens LC, Curley SA, Fang B. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res 62(13):3620-5, 2002. PMID: 12097263.
90. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, Curley SA, Stephens LC, Fang B. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 61:3330-8, 2001. PMID: 11309289.
91. Koch PE, Guo ZS, Kagawa S, Gu J, Roth JA, Fang B. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. Mol Ther 3:278-83, 2001. PMID: 11273768.
92. Kagawa S, Gu J, Honda T, McDonnell TJ, Swisher SG, Roth JA, Fang B. Deficiency of caspase-3 in MCF7 cells blocks Bax-mediated nuclear fragmentation but not cell death. Clin Cancer Res 7:1474-80, 2001. PMID: 11350920.
93. Kagawa S, Gu J, Swisher SG, Ji L, Roth JA, Lai D, Stephens LC, Fang B. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res 60:1157-61, 2000. PMID: 10728665.
94. Perumal K, Gu J, Reddy R. Evolutionary conservation of post-transcriptional 3' end adenylation of small RNAs: S. cerevisiae signal recognition particle RNA and U2 small nuclear RNA are post-transcriptionally adenylated. Mol. Cell. Biochem 208:99-109, 2000.
95. Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA, Fang B. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 60:5359-64, 2000. PMID: 11034071.
96. Chen Y, Sinha K, Perumal K, Gu J, Reddy R. Accurate 3'-end processing and adenylation of human signal recognition particle RNA and Alu RNA in vitro. J. Biol. Chem 273:35023-35031, 1998.
97. Sinha K, Gu J, Chen Y, Reddy R. Adenylation of small RNAs in human cells. J. Biol. Chem 273:6853-6859, 1998.
98. Gu J, Shimba S, Nomura N, Reddy R. Characterization of a novel nuclear RNA-binding protein p110nrb. Biochim. Biophys. Acta 1399:1-9, 1998.
99. Gu J, Shumyatsky G, Makan N, Reddy R. Formation of 2', 3'-cyclic phosphates at the 3'-end of human U6 small nuclear RNA in vitro: identification of 2', 3'-cyclic phosphates at the 3'-end of human SRP and MRP RNAs. J. Biol. Chem 272:21989-21993, 1997.
100. Gu J, Patton JR, Shimba S, Reddy R. Localization of modified nucleotides in S. pombe spliceosomal small nuclear RNAs: modified nucleotides are clustered in functionally important regions. RNA 2:909-918, 1996.

Invited Articles

1. Gu J, Wang Y, Wu X. MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Des. e-Pub 9/25/2012. PMID: 23092349.
2. Chang DW, Gu J, Wu X. Germline prognostic markers for urinary bladder cancer: Obstacles and opportunities. Urol Oncol 30(4):524-32, 7/2012. PMID: 22742565.
3. Gu J, Wu X. Genetic Susceptibility to Bladder Cancer Risk and Outcome. Personalized Medicine 8(3):365-74, 5/2011.
4. Saeki N, Gu J, Yoshida T, Wu X. Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res 16(14):3533-8, 7/2010. e-Pub 5/2010. PMCID: PMC2905486.
5. Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol 5(7):745-55, 7/2009. PMID: 19442035.
6. Wu X, Ros MM, Gu J, Kiemeney L. Epidemiology and genetic susceptibility to bladder cancer. BJU Int 102(9 Pt B):1207-15, 11/2008. PMID: 19035883.
7. Horikawa Y, Gu J, Wu X. Genetic susceptibility to bladder cancer with an emphasis on gene-gene and gene-environmental interactions. Curr Opin Urol 18:493-8, 2008.
8. Wu X, Lin X, Dinney CP, Gu J, Grossman HB. Genetic polymorphism related to bladder cancer. Front Biosc 12:192-213, 2007.
9. Wu X, Gu J, Spitz MR. Mutagen sensitivity: a genetic predisposing factor for cancer. Cancer Res 67:3493-5, 2007.
10. Gu J, Grossman HB, Dinney CP, Wu X. The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. Pharmacogenomics 6:575-84, 2005.
11. Gu J, Fang B. Telomerase promoter-driven cancer gene therapy. Cancer Biol Ther 2:S64-70, 2003.
12. Gu J, Chen Y, Reddy R. Small RNA database. Nucleic Acid Res 26:160-162, 1998.

Book Chapters

1. Gu J, Wu X. MicroRNAs in Esophageal Cancer. In: MicroRNAs in Cancer Translational Research. Ed(s) William Cho. Springer Science, 201-222, 2011.
2. Wu X, Gu J. Pharmacogenetics of lung cancer. In: Lung Cancer: Prevention, Management and Emerging Therapies. Ed(s) Stewart D. Humana Press, 87-106, 2010.
3. Wu X, Gu J, Spitz MR. Strategies to identify pharmacogenomic biomarkers: candidate gene, pathway-based, and genome-wide approaches. In: Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. Ed(s) Federico I. Humana Press, 353-370, 2009.
4. Wu X, Gu J. Pharmacogenetics in cancer chemotherapy. In: Molecular Epidemiology: Applications in Cancer and Other Human Diseases. Ed(s) Rebbeck TR, Ambrosone CB, Shields PG. Informa Healthcare USA, Inc. New York, 29-38, 2008.
5. Hazra A, Gu J, Wu X. Genetic susceptibility to bladder cancer. In: Textbook of Bladder Cancer. Ed(s) Lerner SP, Schoenberg MP, Sternberg CN. Martin Dunitz & Parthenon Publishing, 27-36, 2006.

Grant & Contract Support

Title: MD Anderson Cancer Center SPORE in GU Cancer, Project 2: Markers of susceptibility as predictors of bladder cancer recurrence
Funding Source: NIH/NCI
Role: Co-Investigator: Project 2
Principal Investigator: Colin Dinney
Duration: 9/15/2012 - 8/31/2017
 
Title: Molecular Pathways Linking Obesity and RCC Tumorigenesis
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Xifeng Wu
Duration: 9/1/2012 - 6/30/2016
 
Title: MD Anderson Cancer Cener Prostate SPORE Project 5. Separating the Chaff from the Wheat: Identifying Patients at Minimal Risk for Prostate Cancer Progression
Funding Source: NIH/NCI
Role: Project co-leader
Principal Investigator: Christopher Logothetis
Duration: 9/1/2012 - 8/31/2014
 
Title: UT Southwestern Medical, UT SPORE in Lung Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: John Minna
Duration: 9/1/2008 - 4/30/2013
 
Title: MD Anderson Head & Neck SPORE
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Scott Lippman
Duration: 8/1/2008 - 7/31/2013
 
Title: Telomere dysfunction and bladder cancer risk
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 7/1/2008 - 6/30/2013
 
Title: Genetic Instability and Risk for Esophageal Carcinoma
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Xifeng Wu
Duration: 3/1/2008 - 2/28/2013
 
Title: Genome-Wide Association Analysis of Bladder Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Xifeng Wu
Duration: 3/1/2008 - 2/28/2013

Last updated: 9/3/2013